Search results for "Anticoagulation"
Apixaban associated with lower risk of GI bleeding compared to other DOACs
Apixaban users experienced similar rates of ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality as patients taking other direct oral anticoagulants (DOACs), a retrospective analysis found.
https://immattersacp.org/weekly/archives/2022/11/01/1.htm
1 Nov 2022
Apixaban safer, more effective than rivaroxaban for afib with heart disease, study finds
Apixaban was associated with a lower rate of ischemic stroke or systemic embolism and a lower rate of bleeding in a propensity-matched cohort study of commercially insured patients with atrial fibrillation (AF) and valvular heart disease.
https://immattersacp.org/weekly/archives/2022/10/18/2.htm
18 Oct 2022
AHA scientific statement offers guidance on LV thrombus
Among other recommendations, clinicians should treat patients with left ventricular (LV) thrombus after myocardial infarction using oral anticoagulants for three months, the American Heart Association (AHA) said.
https://immattersacp.org/weekly/archives/2022/09/20/4.htm
20 Sep 2022
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2022/09/latest-updates-on-acps-priorities-initiatives.htm
1 Sep 2022
MKSAP Quiz: 6-month history of intermittent claudication
A 68-year-old man is evaluated for a 6-month history of intermittent claudication. His symptoms have been slowly progressive but are not life limiting. Medical history is significant for hypertension, hyperlipidemia, and carotid artery stenosis treated with left carotid endarterectomy. He is a former smoker but quit 10 years ago. Following a physical exam and lab studies, what is the most appropriate treatment to reduce this patient's cardiovascular risk?
https://immattersacp.org/weekly/archives/2022/08/23/3.htm
23 Aug 2022
Risks and benefits of procedure versus medication in afib vary by individual
A modeling study found that left atrial appendage occlusion could be an alternative to oral anticoagulants in patients at high bleeding risk but that the combination of risks for stroke and bleeding should be considered on an individual basis.
https://immattersacp.org/weekly/archives/2022/08/16/4.htm
16 Aug 2022
Medication adherence affecting cardiovascular outcomes even in clinical trials
Two new analyses of recent cardiology trials highlighted the prevalence and potential adverse effects of nonadherence to medications.
https://immattersacp.org/weekly/archives/2022/08/16/2.htm
16 Aug 2022
Diltiazem may increase bleeding risk when coadministered with DOACs in afib
A study of patients with atrial fibrillation in one U.S. health system found a 56% higher risk for bleeding-related hospitalization associated with concomitant use of diltiazem and a direct-acting oral anticoagulant (DOAC) versus a DOAC alone.
https://immattersacp.org/weekly/archives/2022/07/12/5.htm
12 Jul 2022
MKSAP Quiz: Multiple segmental pulmonary emboli
A 65-year-old man is diagnosed with multiple segmental pulmonary emboli in the right lung. He has no other medical problems, and he takes no medications. He is alert and engaged in shared decision making. After a physical exam and discussion with the patient, what is the appropriate treatment recommendation?
https://immattersacp.org/weekly/archives/2022/05/31/3.htm
31 May 2022
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022